Literature DB >> 11377649

Single nucleotide polymorphism in prohibitin 3' untranslated region and breast-cancer susceptibility.

E R Jupe, A A Badgett, B R Neas, M A Craft, D S Mitchell, R Resta, J J Mulvihill, C E Aston, L F Thompson.   

Abstract

The RNA encoded by the 3' untranslated region of the prohibitin gene arrests cell proliferation by blocking the transition between the G1 and S phases of the cell cycle. The product of a variant allele (T allele) is inactive. We did a case-control study of prohibitin genotype in 205 women with breast cancer and 1046 healthy controls. The results showed an association between the T allele and breast cancer in women who reported a first-degree relative with the disease (odds ratio 2.5, p=0.005). An even stronger association was found in a subset of women diagnosed at or before age 50 years (4.8, p=0.003). These data suggest that prohibitin genotyping has value in assessing risk of breast cancer in women aged 50 years or younger with at least one first-degree relative with the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377649     DOI: 10.1016/s0140-6736(00)04747-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  25 in total

1.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

Review 2.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

3.  Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells.

Authors:  Sharmila Manjeshwar; Megan R Lerner; Xiao-Ping Zang; Dannielle E Branam; J Thomas Pento; Mary M Lane; Stan A Lightfoot; Daniel J Brackett; Eldon R Jupe
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

4.  Detecting DNA and RNA and Differentiating Single-Nucleotide Variations via Field-Effect Transistors.

Authors:  Kevin M Cheung; John M Abendroth; Nako Nakatsuka; Bowen Zhu; Yang Yang; Anne M Andrews; Paul S Weiss
Journal:  Nano Lett       Date:  2020-08-03       Impact factor: 11.189

5.  Modifying effect of MDM4 variants on risk of HPV16-associated squamous cell carcinoma of oropharynx.

Authors:  Hongping Yu; Erich M Sturgis; Zhensheng Liu; Li-E Wang; Qingyi Wei; Guojun Li
Journal:  Cancer       Date:  2011-08-05       Impact factor: 6.860

6.  Association of 758 G/A polymorphism of 3'untranslated region of prohibitin with risk of gastric cancer.

Authors:  Fenfen Xiang; Zhenhua Ni; Yueping Zhan; Jian Xu; Rong Wu; Xiangdong Kang
Journal:  J Clin Lab Anal       Date:  2017-03-13       Impact factor: 2.352

Review 7.  The role and therapeutic potential of prohibitin in disease.

Authors:  Arianne L Theiss; Shanthi V Sitaraman
Journal:  Biochim Biophys Acta       Date:  2011-02-04

8.  Prohibitins are required for cancer cell proliferation and adhesion.

Authors:  Claudia Sievers; Gwendolyn Billig; Kathleen Gottschalk; Thomas Rudel
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

9.  Molecular characterization, tissue expression profile and SNP analysis of the porcine NR1H4 gene.

Authors:  Hu Yang; Jun Jiang; Xingli Xu; Jun He; Changqing He; Haiming Ma
Journal:  Mol Biol Rep       Date:  2014-07-18       Impact factor: 2.316

10.  Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx.

Authors:  Zhongming Lu; Erich M Sturgis; Lijun Zhu; Hua Zhang; Ye Tao; Peng Wei; Qingyi Wei; Guojun Li
Journal:  Mol Carcinog       Date:  2017-11-13       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.